Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8,395.00
Bid: 8,393.00
Ask: 8,396.00
Change: -20.00 (-0.24%)
Spread: 3.00 (0.04%)
Open: 8,380.00
High: 8,414.00
Low: 8,354.00
Yest. Close: 8,415.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 3-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

Fri, 7th May 2021 13:15

* EMA reviews AstraZeneca shot for Guillain-Barre syndrome

* Rare nerve syndrome also linked some vaccinations in past

* EMA assessing heart inflammation with Pfizer, Moderna

* Studies into possible links to rare blood clots ongoing
(Adds BioNTech, Pfizer statement)

May 7 (Reuters) - Europe's medicines regulator is reviewing
reports of a rare nerve-degenerating disorder in people who
received AstraZeneca's COVID-19 shots, raising fresh
questions about potential side-effects of the vaccine.

As part of a regular review of safety reports for the
vaccine, Vaxzevria, the safety committee of the European
Medicines Agency (EMA), is analysing data provided by
AstraZeneca on cases of Guillain-Barre syndrome (GBS), it said
on Friday, without specifying the number of cases.

The Anglo-Swedish drugmaker did not immediately respond to a
request for comment.

The move comes after the EMA found last month that COVID-19
vaccines from both AstraZeneca and Johnson & Johnson may
have caused very rare blood clotting cases.

While the regulator has said the benefits of AstraZeneca's
cheap and easily transportable vaccine in fighting the deadly
pandemic outweigh any risks, several European countries have
limited use to older age groups or suspended use altogether.

The EMA has also backed J&J's vaccine, which is based on a
similar technology to AstraZeneca's.

The regulator said GBS was identified as a possible adverse
event that needed to be specifically monitored during the
vaccine's conditional approval process, adding it had requested
more detailed data on the cases from AstraZeneca.


GBS is a rare neurological condition in which the body's
immune system attacks the protective coating on nerve fibres.
Most cases follow a bacterial or viral infection.

The condition has been linked in the past to vaccinations -
most notably to a vaccination campaign during a swine flu
outbreak in the United States in 1976, and decades later to the
vaccine used during the 2009 H1N1 flu pandemic.

However, researchers have found the chances of developing
GBS after vaccination are extremely small.

On Friday, the EMA also said it was looking into reports of
heart inflammation with Pfizer-BioNTech's
vaccine and Moderna's shot. It said there was no
indication at present that these cases were due to the vaccines.

Both the Pfizer-BioNTech and Moderna vaccines use new mRNA
technology to build immunity.

Last week, the U.S. Centers for Disease Control and
Prevention said it had not found a link between heart
inflammation and COVID-19 vaccines.

Pfizer and BioNTech said in a joint statement they would
support the EMA's review and that they also saw no indication of
a causal link after more than 450 million doses had been
administered globally.

Myocarditis was not observed at a higher rate than would be
expected in the general population, they added.

Moderna did not immediately respond to a request for
(Reporting by Pushkala Aripaka and Yadarisa Shabong in
Bengaluru, Ludwig Burger in Frankfurt and Kate Kelland in
London; Editing by Gareth Jones and Mark Potter)

More News

Swiss health ministry data shows vaccinated people seldom hit by COVID-19

By John MillerZURICH, June 24 (Reuters) - Switzerland's move to allow large public events with 10,000-plus people from Saturday comes as government data appears to show vaccines are helping control new infections that are mostly hitting people who...

24 Jun 21 17:36

Oxford researchers say they developed blood test predictor of vaccine efficacy

By Ludwig BurgerFRANKFURT, June 24 (Reuters) - Researchers at Oxford University said on Thursday they have developed a method to predict the efficacy of new COVID-19 vaccines based on a blood test, potentially offering a short-cut around massive c...

24 Jun 21 16:01

UPDATE 2-FTSE 100 rises on dovish BoE; miners, pharma stocks lead gains

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* BoE maintains loose monetary policy* AstraZeneca, Anglo American top boosts to FTSE 100* Carnival falls after $2 billion quarterly loss* FT...

24 Jun 21 09:58

AstraZeneca, MSD prostate cancer drug gets China green light

(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.

24 Jun 21 07:34

Seychelles looking to diversity economy beyond tourism post-COVID - minister

By Omar MohammedNAIROBI, June 23 (Reuters) - Seychelles said on Wednesday it is looking to diversify its economy beyond its mainstay of tourism into areas such as fisheries after visitor numbers were battered by restrictions to arrest the spread o...

23 Jun 21 13:37

Wednesday broker round-up

(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.

23 Jun 21 13:04

UPDATE 1-GSK pledges sales boost after split from consumer arm

(Adds details, background)June 23 (Reuters) - New GSK, the pharmaceuticals business being separated from its consumer health operations, pledged to increase sales by more than 5% a year to 2026, the group said on Wednesday, as it published details...

23 Jun 21 11:35

UPDATE 2-GSK's drugs arm to get $11 bln windfall from consumer spin-off

* GSK consumer arm to be demerged in middle of 2022* Drugs business to get 8 bln stg dividend from consumer arm* Lower debt ratio, dividend to boost finances of drugs arm (Adds CEO comment, detail, background)By Ludwig Burger and Pushkala AripakaJun...

23 Jun 21 11:35

UPDATE 3-GSK's drugs arm to get $11 bln booster from consumer spin-off

* GSK consumer arm to be demerged in middle of 2022* Drugs business to get 8 bln stg dividend from consumer arm* Lower debt ratio, dividend to boost finances of drugs arm (Adds details on dividend, debt, Pfizer comment, updates shares)By Ludwig Bur...

23 Jun 21 11:35

GSK sets out plans for listing of consumer products venture

June 23 (Reuters) - Britain's GSK on Wednesday unveiled a detailed plan to spin off its consumer healthcare venture with Pfizer into a separate company by the middle of next year, as the pharmaceutical giant sharpens its focus on prescription med...

23 Jun 21 11:10

Delta plus variant reclassified as 'variant of concern', experts sanguine for now

(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".

23 Jun 21 10:47

AstraZeneca's 'Orpathys' gets conditional approval in China

(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.

23 Jun 21 07:33

Chile weighing issue of third booster dose of COVID-19 vaccine

By Fabian CamberoSANTIAGO, June 22 (Reuters) - Chile is studying the possibility of issuing a third, booster dose of COVID-19 vaccines, its president said on Tuesday, as the country seeks to beat back the latest wave of infections amid questions a...

22 Jun 21 20:25

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

22 Jun 21 20:16

UPDATE 2-AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study

* Variants may cause few breakthrough infections in vaccinated* Researchers find no evidence of widespread virus escape* Past infection with B117/Alpha confers broad protection (Recasts, adds details on Pfizer-BioNTech vaccine)By Ludwig Burger and ...

22 Jun 21 19:53

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.